Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [912]

OncoAlert and ecancer ASCO roundup - Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer ASCO roundup - Day 1

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo...

Dr Joshua Sabari and Dr Anna Minchom

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with...

Dr Jonathan Spicer - McGill University, Montreal, Canada

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC ( Dr Jonathan Spicer - McGill University, Montreal, Canada )

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for...

Dr Ian Chau - The Royal Marsden, London, UK

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC ( Dr Ian Chau - The Royal Marsden, London, UK )

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first...

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small...

Dr Erminia Massarelli - City of Hope, Duarte, USA

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer ( Dr Erminia Massarelli - City of Hope, Duarte, USA )

SEMS trial: result of a prospective, multi-institutional phase II clinical...

Dr Sia Daneshmand - University of Southern California, Los Angeles, USA

SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma ( Dr Sia Daneshmand - University of Southern California, Los Angeles, USA )

Current treatment standards for primary ovarian cancer

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Current treatment standards for primary ovarian cancer ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

Evolving medical treatment in advanced/recurrent endometrial cancer

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Evolving medical treatment in advanced/recurrent endometrial cancer ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

ITACA NSCLC study: Final results

Prof Silvia Novello - University of Turin, Turin, Italy

ITACA NSCLC study: Final results ( Prof Silvia Novello - University of Turin, Turin, Italy )

More from ecancer